BioSpace News Archive

According to Vision Research Reports, the global in vitro diagnostics market size is expected to rake around US$ 125.5 billion by 2030.

According to Vision Research Reports, the global medical device outsourcing market size was valued at USD 106.92 billion in 2021, and is predicted to be worth around USD 291.93 billion by 2030, registering a CAGR of 11.1% during the forecast period 2022 to 2030.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced it will report financial results for the second quarter 2022 after market close on Tuesday, July 26, 2022.

According to Vision Research Reports, the global point of care infectious disease testing market size was valued at US$ 2.3 billion in 2021 and is expected to reach around USD 4.1 billion by 2030 with a CAGR of 17% from 2022 to 2030.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering of 10,810,811 shares of its common stock at a price to the public of $18.50 per share.

ByteDance has pitched into life sciences. Last October, this internet tech giant invested in the biotech startup Shuimu BioSciences (Shuimu), a company leveraging the power of cryogenic electron microscopy (cryo-EM) and AI to revolutionize drug discovery.

On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies.

Evofem Biosciences, Inc., announced that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products, a peer-reviewed article defining and reconfirming the mechanism of action of Phexxi®.

Altamira Therapeutics today announced the publication of a peer-reviewed article in the scientific journal Biomaterials Advances titled, “Peptide-siRNA nanoparticles targeting NF-κB p50 mitigate experimental abdominal aortic aneurysm (AAA) progression and rupture” that covers a study conducted by a research group at Washington University, St. Louis, MO.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company’s Board, effective July 11, 2022.